FOXO1在口腔鳞状细胞癌中的研究进展

国际肿瘤学杂志››2022,Vol. 49››Issue (10): 612-614.doi:10.3760/cma.j.cn371439-20220414-00121

FOXO1在口腔鳞状细胞癌中的研究进展

杨帆¹, 管晓燕^1,², 刘建国², 肖琳琳^1,², 岳超弈³, 龙茜^1,², 廖成成^1,²()

¹遵义医科大学附属口腔医院正畸科二组，遵义 563000
²贵州省普通高等学校口腔疾病研究特色重点实验室，遵义 563000
³遵义医科大学医学与科技学院，遵义 563000

收稿日期:2022-04-14修回日期:2022-05-16出版日期:2022-10-08发布日期:2022-12-01
通讯作者:廖成成 E-mail:lcc_950330@163.com
基金资助:
国家重点研发计划(2016YFC1102800);贵州省医用生物材料研发人才基地项目(QianRenLingFa [2018] 3)

Research progress of FOXO1 in oral squamous cell carcinoma

Yang Fan¹, Guan Xiaoyan^1,², Liu Jianguo², Xiao Linlin^1,², Yue Chaoyi³, Long Qian^1,², Liao Chengcheng^1,²()

¹Department of Orthodontics Ⅱ， Affiliated Stomatological Hospital of Zunyi Medical University， Zunyi 563000， China
²Guizhou Provincial Key Laboratory of Oral Disease Research in Colleges and Universities， Zunyi 563000， China
³School of Medicine and Technology， Zunyi Medical University， Zunyi 563000， China

Received:2022-04-14Revised:2022-05-16Online:2022-10-08Published:2022-12-01
Contact:Liao Chengcheng E-mail:lcc_950330@163.com
Supported by:
National Key Research and Development Program(2016YFC1102800);Guizhou Province Medical Biomaterials Research and Development Talent Base Project(QianRenLingFa [2018] 3)

摘要/Abstract

摘要：

叉头框蛋白O1（FOXO1）是一种肿瘤抑制因子。在口腔鳞状细胞癌中，研究证实FOXO1能够抑制肿瘤细胞氧化应激、干细胞性和上皮间质转化，并促进肿瘤细胞自噬和凋亡。FOXO1可作为治疗口腔鳞状细胞癌的潜在靶点。

杨帆, 管晓燕, 刘建国, 肖琳琳, 岳超弈, 龙茜, 廖成成. FOXO1在口腔鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 612-614.

Yang Fan, Guan Xiaoyan, Liu Jianguo, Xiao Linlin, Yue Chaoyi, Long Qian, Liao Chengcheng. Research progress of FOXO1 in oral squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(10): 612-614.

参考文献27

[1]	石雨, 陈曦, 许梦琪, 等. 沉默PSIP1基因对口腔鳞状细胞癌细胞迁移及侵袭的影响[J]. 国际肿瘤学杂志, 2022, 49(3): 129-133. DOI: 10.3760/cma.j.cn371439-20210917-00022. doi:10.3760/cma.j.cn371439-20210917-00022
[2]	Saikishore R, Velmurugan P, Ranjithkumar D, et al. The circular RNA-miRNA axis: a special RNA signature regulatory transcriptome as a potential biomarker for OSCC[J]. Mol Ther Nucleic Acids, 2020, 22: 352-361. DOI: 10.1016/j.omtn.2020.09.001. doi:10.1016/j.omtn.2020.09.001
[3]	Farhan M, Wang H, Gaur U, et al. FOXO signaling pathways as therapeutic targets in cancer[J]. Int J Biol Sci, 2017, 13(7): 815-827. DOI: 10.7150/ijbs.20052. doi:10.7150/ijbs.20052pmid:28808415
[4]	Soh R, Hardy A, Zur Nieden NI. The FOXO signaling axis displays conjoined functions in redox homeostasis and stemness[J]. Free Radic Biol Med, 2021, 169: 224-237. DOI: 10.1016/j.freeradbiomed.2021.04.022. doi:10.1016/j.freeradbiomed.2021.04.022
[5]	Calissi G, Lam EW, Link W. Therapeutic strategies targeting FOXO transcription factors[J]. Nat Rev Drug Discov, 2021, 20(1): 21-38. DOI: 10.1038/s41573-020-0088-2. doi:10.1038/s41573-020-0088-2pmid:33173189
[6]	Liao C, Wang Q, An J, et al. Partial EMT in squamous cell carcinoma: a snapshot[J]. Int J Biol Sci, 2021, 17(12): 3036-3047. DOI: 10.7150/ijbs.61566. doi:10.7150/ijbs.61566pmid:34421348
[7]	Zheng M, Cao MX, Luo XJ, et al. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells[J]. J Cell Mol Med, 2019, 23(10): 6942-6954. DOI: 10.1111/jcmm.14579. doi:10.1111/jcmm.14579pmid:31368152
[8]	Yang X, Sun T, Zhao Y, et al. 4sc-202 and Ink-128 cooperate to reverse the epithelial to mesenchymal transition in OSCC[J]. Oral Dis, 2021. DOI: 10.1111/odi.13860. doi:10.1111/odi.13860
[9]	廖成成, 安家兴, 谭张雪, 等. 口腔鳞状细胞癌干细胞的治疗靶点及应用前景[J]. 中国组织工程研究, 2021, 25(7): 1096-1103. DOI: 10.3969/j.issn.2095-4344.2126. doi:10.3969/j.issn.2095-4344.2126
[10]	Liu W, Chen G. Regulation of energy metabolism in human pluripotent stem cells[J]. Cell Mol Life Sci, 2021, 78(24): 8097-8108. DOI: 10.1007/s00018-021-04016-0. doi:10.1007/s00018-021-04016-0pmid:34773132
[11]	Saha T, Lukong KE. Breast cancer stem-like cells in drug resistance: a review of mechanisms and novel therapeutic strategies to overcome drug resistance[J]. Front Oncol, 2022, 12: 856974. DOI: 10.3389/fonc.2022.856974. doi:10.3389/fonc.2022.856974
[12]	Dorna D, Paluszczak J. The emerging significance of histone lysine demethylases as prognostic markers and therapeutic targets in head and neck cancers[J]. Cells, 2022, 11(6): 1023. DOI: 10.3390/cells11061023. doi:10.3390/cells11061023
[13]	Shi C, Wang L, Sen P. The eroding chromatin landscape of aging stem cells[J]. Transl Med Aging, 2020, 4: 121-131. DOI: 10.1016/j.tma.2020.08.002. doi:10.1016/j.tma.2020.08.002
[14]	Onorati AV, Dyczynski M, Ojha R, et al. Targeting autophagy in cancer[J]. Cancer, 2018, 124(16): 3307-3318. DOI: 10.1002/cncr.31335. doi:10.1002/cncr.31335pmid:29671878
[15]	Zhou L, Guo J, Jia R. Oncogene SRSF3 suppresses autophagy via inhibiting BECN1 expression[J]. Biochem Biophys Res Commun, 2019, 509(4): 966-972. DOI: 10.1016/j.bbrc.2019.01.048. doi:10.1016/j.bbrc.2019.01.048
[16]	Xing YQ, Li A, Yang Y, et al. The regulation of FOXO1 and its role in disease progression[J]. Life Sci, 2018, 193: 124-131. DOI: 10.1016/j.lfs.2017.11.030. doi:S0024-3205(17)30607-0pmid:29158051
[17]	Liang J, Yang B, Zhou X, et al. Stimuli-responsive drug delivery systems for head and neck cancer therapy[J]. Drug Deliv, 2021, 28(1): 272-284. DOI: 10.1080/10717544.2021.1876182. doi:10.1080/10717544.2021.1876182pmid:33501883
[18]	Lin CC, Yang CC, Hsiao LD, et al. Carbon monoxide releasing molecule-3 enhances heme oxygenase-1 induction via ROS-dependent FoxO1 and Nrf2 in brain astrocytes[J]. Oxid Med Cell Longev, 2021, 2021: 5521196. DOI: 10.1155/2021/5521196. doi:10.1155/2021/5521196
[19]	Remadevi V, Muraleedharan P, Sreeja S. FOXO1: a pivotal pioneer factor in oral squamous cell carcinoma[J]. Am J Cancer Res, 2021: 11(10): 4700-4710. pmid:34765288
[20]	Zhang Y, Xiong Y, Zhou J, et al. FoxO1 expression in osteoblasts modulates bone formation through resistance to oxidative stress in mice[J]. Biochem Biophys Res Commun, 2018, 503(3): 1401-1408. DOI: 10.1016/j.bbrc.2018.07.055. doi:10.1016/j.bbrc.2018.07.055
[21]	Sekar M, Thirumurugan K. Autophagy: a molecular switch to regulate adipogenesis and lipolysis[J]. Mol Cell Biochem, 2022, 477(3): 727-742. DOI: 10.1007/s11010-021-04324-w. doi:10.1007/s11010-021-04324-wpmid:35022960
[22]	Zhao C, Zhang Z, Dai X, et al. Actein antagonizes oral squamous cell carcinoma proliferation through activating FoxO1[J]. Pharmacology, 2021, 106(9-10): 551-563. DOI: 10.1159/000 515601. doi:10.1159/000 515601
[23]	Song H, Lai L, Liu M, et al. Investigating the role and mechanism of microRNA-196a in oral squamous cell carcinoma by targeting FOXO1[J]. Exp Ther Med, 2020, 19(6): 3707-3715. DOI: 10.3892/etm.2020.8614. doi:10.3892/etm.2020.8614pmid:32346435
[24]	Xu Y, Pan S, Jiang W, et al. Effects of propofol on the development of cancer in humans[J]. Cell Prolif, 2020, 53(8): e12867. DOI: 10.1111/cpr.12867. doi:10.1111/cpr.12867
[25]	Shi F, Li T, Liu Z, et al. FOXO1: another avenue for treating digestive malignancy?[J]. Semin Cancer Biol, 2018, 50:124-131. DOI: 10.1016/j.semcancer.2017.09.009. doi:S1044-579X(17)30183-9pmid:28965871
[26]	Silva P, Latruffe N, Gaetano G. Wine consumption and oral cavity cancer: friend or foe, two faces of Janus[J]. Molecules, 2020, 25(11): 2569. DOI: 10.3390/molecules25112569. doi:10.3390/molecules25112569
[27]	Körholz K, Ridinger J, Krunic D, et al. Broad-spectrum HDAC inhibitors promote autophagy through FOXO transcription factors in neuroblastoma[J]. Cells, 2021, 10(5): 1001. DOI: 10.3390/cells10051001. doi:10.3390/cells10051001